Search research articles
Contact Us
Filters
Showing results (61-70 of 66) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 66 results.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|
December 30, 2014
[Characteristics and treatment outcomes in 822 adult patients with acute myeloid leukemia:a single center experience]
Dong Lin, Chunlin Zhou, Hui Wei, et al.
Blood Science (Baltimore, Md.)
|
June 24, 2024
Ivosidenib in Chinese patients with relapsed or refractory isocitrate dehydrogenase 1 mutated acute myeloid leukemia: a registry study
Mingyuan Sun, Qingsong Yin, Yang Liang, et al.
Genomics, Proteomics & Bioinformatics
|
April 8, 2017
GSA: Genome Sequence Archive<sup/>
Yanqing Wang, Fuhai Song, Junwei Zhu, et al.
Advances in Therapy
|
July 28, 2022
Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies
Wei Xu, Shenmiao Yang, Constantine S Tam, et al.
Blood Advances
|
September 8, 2023
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study
Stephen Opat, Alessandra Tedeschi, Bei Hu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 16, 2021
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
Stephen Opat, Alessandra Tedeschi, Kim Linton, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 66) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 66 results.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|
December 30, 2014
[Characteristics and treatment outcomes in 822 adult patients with acute myeloid leukemia:a single center experience]
Dong Lin, Chunlin Zhou, Hui Wei, et al.
Blood Science (Baltimore, Md.)
|
June 24, 2024
Ivosidenib in Chinese patients with relapsed or refractory isocitrate dehydrogenase 1 mutated acute myeloid leukemia: a registry study
Mingyuan Sun, Qingsong Yin, Yang Liang, et al.
Genomics, Proteomics & Bioinformatics
|
April 8, 2017
GSA: Genome Sequence Archive<sup/>
Yanqing Wang, Fuhai Song, Junwei Zhu, et al.
Advances in Therapy
|
July 28, 2022
Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies
Wei Xu, Shenmiao Yang, Constantine S Tam, et al.
Blood Advances
|
September 8, 2023
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study
Stephen Opat, Alessandra Tedeschi, Bei Hu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 16, 2021
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
Stephen Opat, Alessandra Tedeschi, Kim Linton, et al.
Page
of 7